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ABSTRACT
Introduction: It has recently been demonstrated that CYP2C19 
activity may be influenced not only by CYP2C19 polymorphism, 
but also cytochrome P450 oxidoreductase (POR) protein abun-
dance in human liver microsomes. The human POR gene is highly 
polymorphic and a common POR*28 allele is associated with 
increased POR activity, which may result in increased CYP P450 
activity (including CYP2C19).
The aim of the current study was to evaluate the association 
between POR and CYP2C19 polymorphisms and CYP2C19 sub-
strate pharmacokinetics, i.e. pantoprazole, in Polish Caucasian 
healthy volunteers.
Materials and methods: The study enrolled 30 subjects, geno-
typed for rs4244285 (681G>A, CYP2C19*2), rs12248560 (−806C>T, 
CYP2C19*17) and rs1057868 (31696C>T, POR*28). Pantoprazole 
 
concentration in plasma was determined by validated high-
performance liquid-chromatography method 1 h, 2 h, 3 h, 4 h, 6 h 
and 8 h after a single oral 40 mg dose of the drug.
Results: No significant differences in the drug concentrations 
between POR*1/*1, POR*1/*28 and POR*28/*28 carriers were 
observed. Multivariate analysis revealed that the CYP2C19 geno-
type significantly influenced all the investigated pharmacoki-
netic parameters (p < 0.05), while the POR genotype was not 
associated with any of the parameters.
Conclusions: The results of the current study suggest that POR 
polymorphism does not significantly influence pantoprazole 
pharmacokinetics.
Keywords: pantoprazole; pharmacokinetics; pharmacogene-
tics; POR; cytochrome P450 oxidoreductase.
ABSTRAKT
Wstęp: Genetycznie uwarunkowana aktywność enzymów meta-
bolizujących leki może mieć znaczenie dla bezpieczeństwa i sku-
teczności leczenia. We wcześniejszych badaniach wykazano, 
że na aktywność enzymatyczną CYP2C19 może wpływać nie 
tylko polimorfizm genu kodującego ten cytochrom, lecz także 
zawartość reduktazy cytochromu P450 (POR) w mikrosomach 
ludzkich hepatocytów. Ludzki gen POR wykazuje dużą zmien-
ność, a allel POR*28 jest związany ze zwiększoną aktywnością 
reduktazy, co w konsekwencji może prowadzić do zwiększonej 
aktywności układu CYP P450, w tym enzymu CYP2C19.
Celem badania było określenie związku pomiędzy polimorfi-
zmem genu POR a parametrami farmakokinetycznymi panto-
prazolu, substratu CYP2C19 w grupie zdrowych ochotników. 
W analizie uwzględniono także warianty genu CYP2C19.
Materiały i metody: U 30 osób, u których wykonano badanie 
pod kątem występowania jedno nukleotydowych polimorfizmów: 
 
rs4244285 (681G>A, CYP2C19*2), rs12248560 (−806C>T, CYP2C19*17) 
oraz rs1057868 (31696C>T, POR*28). Stężenia pantoprazolu w oso-
czu zmierzono metodą wysokosprawnej chromatografii cieczo-
wej w ciągu 8 godz. od przyjęcia pojedynczej doustnej dawki 
leku (40 mg).
Wyniki: Nie stwierdzono istotnych różnic w stężeniu panto-
prazolu pomiędzy osobami o różnych genotypach POR (*1/*1, 
*1/*28 i *28/*28). Analiza wieloczynnikowa wykazała, że geno-
typ CYP2C19 istotnie wpływał na wartość wszystkich analizo-
wanych parametrów farmakokinetycznych (p < 0.05), podczas 
gdy genotyp POR nie był istotnie związany z żadnym z nich.
Wnioski: Wyniki badania wskazują, że polimorfizm genu POR 
nie wpływa istotnie na farmakokinetykę pantoprazolu.
Słowa kluczowe: pantoprazol; farmakokinetyka; farmakoge-
netyka; POR; oksydoreduktaza cytochromu P450.
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INTRODUCTION
Recently, Shirasaka et al. demonstrated, assaying human liver 
microsomes (S)-mephenytoin hydroxylase activity, that inter-
individual variability in CYP2C19 activity was due to differ-
ences in CYP2C19 protein content determined by genotypes 
(decreasing from CYP2C19*17/*17 to *2/*2) and cytochrome 
P450 oxidoreductase (POR) protein abundance in human 
liver microsomes [1]. CYP2C19 plays an important role in the 
metabolism of many medications, e.g. proton pump inhibitors, 
antiplatelet drugs, antiepileptics, and antidepressants. Its func-
tion can be partially determined by CYP2C19 polymorphism. 
The available studies demonstrated that individuals homozy-
gous for the inactive CYP2C19*2 allele, resulting in a splicing 
defect, are phenotypically poor metabolizers of CYP2C19 sub-
strates. Likewise, carriers of the CYP2C19*3 allele (premature 
stop codon), present in Asian populations, are categorized 
to CYP2C19 poor metabolizers [2]. Conversely, the CYP2C19*17 
variant allele, harbouring −806C>T substitution in the promoter 
region, is associated with an increased, ultra-rapid enzymatic 
activity of CYP2C19, probably due to its affect on the binding 
of transcription factors that enhance gene transcription [3]. 
Although CYP2C19 activity in liver microsomes from carri-
ers of at least one CYP2C19*17 allele did not differ significantly 
from wild-type homozygous livers, a trend towards increased 
enzymatic rate in CYP2C19*17 livers was noted [4]. Chiba et al. 
estimated in vivo inter-individual variability, i.e. coefficient 
of variation’ in hepatic intrinsic clearance in CYP2C19 poor 
metabolizers (CYP2C19*2/*2, CYP2C19*3/*3 or CYP2C19*2/*3) 
at 25.8%, in extensive metabolizers (CYP2C19*1/*1) at 66.0%, 
intermediate metabolizers (CYP2C19*1/*2 or *3) at 55.8%, and 
ultra-rapid metabolizers (CYP2C19*17/*17) at 6.8% [2].
One of the factors possibly interfering with CYPs activi ty 
is POR, a flavoprotein which as an electron donor plays a key 
role in the catalytic rate of CYPs. The human POR gene is highly 
polymorphic. The most common polymorphism, i.e. POR*28 
is characterized by a change of a single amino acid from ala-
nine to valine (A503V) [5]. The POR*28 allele has been shown 
to be functional, and is associated with increased POR activ-
ity, leading to increased CYP P450 activity (CYP3A4 and 3A5, 
CYP2C19) [6, 7]. As for the interaction between POR and CYP2C19 
polymorphisms, only one study has been published. Saruwatari 
et al. reported that CYP2C19 and POR*28 genotypes produced 
an impact on clobazam and N-desmethylclobazam clearance 
in a Japanese population [8]. However, there is no available 
information on the association of POR*28 and CYP2C19 poly-
morphisms with the pharmacokinetics of CYP2C19 substrates 
in Caucasians. Both populations are different in terms of the 
frequency of CYP2C19*3 polymorphism, which is found in 8.8% 
of Asians and less than 0.1% in Caucasians, and to a lesser range 
for CYP2C9*2, i.e. 28.6% and 12–16%, respectively [9]. As for the 
CYP2C19*17 allele, it is found in 18–28% of subjects of Caucasian 
ancestry and in 0.3–4% of Asian individuals [10]. 
The aim of this study was to evaluate the association 
between POR and CYP2C19 polymorphisms and CYP2C19 
substrate pharmacokinetics, i.e. pantoprazole, in Polish Cau-
casian healthy subjects.
MATERIALS AND METHODS
The study enrolled 30 healthy volunteers (15 males/15 females), 
Polish Caucasians, aged 21–26 years, weighing 52–90 kg. Six 
individuals for each of the following CYP2C19 genotypes 
were recruited: CYP2C19*1/*1, CYP2C19*1/*2, CYP2C19*1/*17, 
CYP2C19*2/*17, and CYP2C19*17/*17 (detailed subject charac-
teristics were previously published in ref. [11]). CYP2C19*2/*2 
individuals were excluded from the current analysis (two 
subjects).
Genotyping for rs4244285 (681G>A, CYP2C19*2), rs12248560 
(−806C>T, CYP2C19*17) and rs1057868 (31696C>T, POR*28) SNPs 
was performed in all study subjects, using genomic DNA iso-
lated from whole blood samples (GeneMATRIX Quick Blood 
DNA Purification Kit, EURx, Poland). Allelic discrimination 
TaqMan assays (Assay IDs: C_25986767_70, C_469857_10, 
C___8890131_30, Life Technologies, USA) and 7500 FAST Real-
Time PCR System (Applied Biosystems) were used for geno-
type determination.
Pantoprazole concentration in plasma was determined 
by a validated high-performance liquid-chromatography 
method with ultraviolet detection following solid phase 
extraction after a single oral 40 mg dose of the drug. Blood 
samples were drawn before drug administration, and then 
at 1 h, 2 h, 3 h, 4 h, 6 h and 8 h post-dose. The analytical pro-
cedures were previously published in detail by Gawrońska-
 -Szklarz et al. [11].
The pharmacokinetic parameters of pantoprazole, i.e. 
clearance/F (F – fraction of a dose absorbed), distribution 
volume, half-life, mean residence time, time to maximum con-
centration and maximum concentration were derived by non-
compartmental analysis using Phoenix WinNonlin 6.2 (Phar-
sight Corporation, Mountain View, USA). For each individual 
the terminal elimination rate constant was determined by 
log-linear regression of the terminal phase of the plasma con-
centration-time curve. The area under the concentration-time 
curve was determined by the linear trapezoidal rule from time 
zero to the time of the last observed concentration [12]. Dif-
ferences between individuals with variant genotypes were 
evaluated using Student t-test and log-transformed values 
of pharmacokinetic parameters. Additionally, multivariate 
analysis of variance (MANOVA) with both CYP2C19 and POR 
genotypes as variables was performed. The level of signifi-
cance was set at 0.05.
The study protocol was approved by the local Ethical Com-
mittee at the Pomeranian Medical University in Szczecin 
(Poland). All performed procedures were in accordance with 
the institutional and/or national research committee, and 
with the 1964 Helsinki declaration and its later amendments or 
comparable ethical standards. Informed consent was obtained 
from all participants included in the study.
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RESULTS
The mean pantoprazole plasma concentrations in the evalu-
ated subjects with different POR genotypes are presented in 
Figure 1. No significant differences in the drug concentrations 
between POR*1/*1, POR*1/*28 and POR*28/*28 carriers were 
observed. Likewise, the values of the pharmacokinetic param-
eters did not differ significantly in both POR groups (Table 1).
pharmacokinetics, but not Helicobacter pylori eradication rate 
in a Turkish population [17]. However, it should be pointed out 
that the effects of antibacterial management depend not only 
on drug concentrations, but also regional bacterial antibiotic 
resistance.
POR activity, and assuming the functional role of POR*28 
variant allele, and also its polymorphism, can be one of the fac-
tors regulating the activity of various CYPs, mainly CYP3A4, 
CYP2B6, with a single report on CYP2C19. However, the results 
are contradictory, and can be partly explained by the ethnic-
ity of studied populations [6, 7, 18, 19, 20]. Our previous data 
demonstrated that POR*28 polymorphism did not affect the 
pharmacokinetics of tacrolimus, a substrate for CYP3A4, in 
Polish-Caucasian kidney transplant patients [21].
The POR*28 allele has been shown to be functional, result-
ing in increased POR activity, and then leading to increased 
CYP P450 activity (CYP3A4 and 3A5, CYP2C19) [6, 7]. However, 
an in vitro report on POR*28 variant activity demonstrated 
only a mild (113%) increase in CYP2C19 catalytic activity, using 
EOMCC (a fluorogenic non-drug agent) as a substrate [5].
The available clinical information on an association between 
POR*28 genotype and CYP2C19 activity has been reported only 
by Saruwatari et al. so far. The authors demonstrated that 
clobazam (CYP2C19 substrate) clearance was significantly 
lower by 18% in CYP2C19 poor metabolizers in comparison 
with homozygous extensive metabolizers among epileptic 
patients of Japanese ancestry. Increased clobazam clearance 
(by 44%) in individuals homozygous for POR*28 allele com-
pared to POR*28 non-carriers was also observed [8]. However, 
the patients of the abovementioned study were co-medicated 
with phenobarbital, phenytoin and zonisamide, which signifi-
cantly affected clobazam clearance, and thus could also have 
impacted the observed pharmacogenetic-pharmacokinetic 
interactions.
Conversely, our in vivo observations in healthy Caucasian 
volunteers did not demonstrate a significant impact of the POR 
polymorphism on pantoprazole pharmacokinetics (a probe 
drug for CYP2C19 activity), as only CYP2C19 genetic status was 
found to significantly affect the drug pharmacokinetics. The 
current results support the in vitro observations of Agraval 
et al., who documented only a weak relationship between 
POR*28 (A503V) polymorphism and CYP2C19 activity in vitro, 
detecting 113% of wild-type CYP2C19 activity in the case of the 
503V variant expressed in E. coli [6]. The differences between 
two clinical observations may stem from known interethnic 
differences in allelic distribution, especially for the CYP2C19 
gene. Similarly, in another study from a Polish population an 
association between POR*28 polymorphism and CYPA4 sub-
strate tacrolimus pharmacokinetics was not found [21]. It should 
also be noted that a relationship between CYP2C19 activity, 
CYP2C19 polymorphism and POR protein content in human 
liver microsomes was revealed [1]. Those findings suggest that 
POR protein abundance in liver microsomes may be a better 
predictor of POR activity than the studied POR polymorphism. 
However, in the case of POR the situation seems relatively com-
plex. The potential confounders list includes not only possible 
FIGURE   1. Mean plasma concentration-time profiles in individuals with 
different POR genotypes after administration of 40 mg pantoprazole as 
a single oral dose. POR polymorphism did not significantly affect the drug 
concentrations within 8 hours after administration
TABLE   1. Pharmacokinetic parameters of pantoprazole in subjects 
stratified according to POR*28 polymorphism
Parameter POR*1/*1  (n = 18)
POR*28 carriers 
(n = 12) p
λz (h⁻1) 0.619 ±0.273 0.568 ±0.185 0.641
t½ (h) 1.274 ±0.424 1.330 ±0.376 0.641
tmax (h) 2.583 ±0.691 2.604 ±0.559 0.848
Cmax (mg/L) 1.588 ±0.514 1.715 ±0.560 0.539
AUC (mg∙h/L) 2.757 ±1.076 2.799 ±1.086 0.906
Vz/F (L) 26.491 ±7.556 27.109 ±6.880 0.732
CL/F (L/h) 16.267 ±8.049 15.817 ±7.755 0.869
MRT (h) 3.456 ±0.704 3.456 ±0.658 0.976
Results presented as mean ±SD; p values calculated by means of the Student 
t-test, using log-transformed values; λz – terminal elimination rate constant; t½ – 
half-life; tmax – time to maximum concentration; Cmax – maximum concentration; 
AUC – the area under the concentration-time curve; Vz/F – distribution volume; 
CL/F – clearance/F (F – fraction of a dose absorbed); MRT – mean residence time 
DISCUSSION
It was documented that the pharmacokinetics of some CYP2C19 
substrates, including pantoprazole, as well as the clinical out-
come of peptic ulcer disease and depression treatment were 
associated with CYP2C19 activity and CYP2C19 gene polymor-
phism [3, 11, 13, 14, 15, 16]. Some recent findings of Karaca et al. 
suggest that CYP2C19 polymorphism affects only pantoprazole 
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genetic variants of the CYP isoenzymes for which POR is an 
obligatory co-enzyme, but also cellular flavin content of the 
POR flavoprotein (e.g. in hepatocytes). The latter factors may 
also explain discrepancies observed in clinical studies.
CONCLUSIONS
A direct measurement of POR activity would be the best meas-
ure of enzymatic function, but along with protein content meas-
urement is not feasible in clinical practice. Further clinical stud-
ies are needed to finally define the role of POR polymorphism 
in the regulation of CYP2C19 activity. Finally, the results of the 
current study suggests that, in contrast to CYP2C19 variants, 
POR genetic polymorphism does not significantly influence 
pantoprazole pharmacokinetics.
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